Hims & Hers (HIMS) Shares Plunge Over 25% After FDA Panel Rejects Emideltide

Hims & Hers Inc. (HIMS) shares suffered one of their steepest declines after the FDA advisory panel voted to reject adding emideltide to the 503A Bulks List.

Regulatory Verdict Sends Shockwaves Through the Market

The FDA advisory panel denied the request to list emideltide, prompting HIMS shares to tumble over 25% and break below their 50‑day moving average.

Reasons Behind the Rejection and Safety Concerns

■Panel members cited an insufficient safety profile and manufacturing inconsistencies.

■A lack of robust clinical data failed to demonstrate emideltide’s superiority over existing FDA‑approved therapies.

■The denial casts doubt on the company’s high‑margin peptide growth trajectory.

Uncertainty in HIMS’s Peptide Expansion Strategy

The firm has been leveraging personalized compounded therapies to extend beyond its core telehealth offerings; the rejection of emideltide undermines this strategic pillar.

Short‑Term Technical Outlook and Investor Sentiment

■The stock is trading below its 50‑day moving average, indicating continued bearish momentum.

■Volatility has risen, reflecting diminished risk appetite and short‑term sell pressure.

■Support levels hover around $9.00 and $8.50; a breach could see further declines.

Captain Rıza Deniz Analysis: The FDA panel’s decision delivers a sharp blow to HIMS’s high‑growth peptide business model. Escalating regulatory risk forces a reassessment of the company’s valuation. In the short term, the stock is trapped at low technical levels, but a favorable final FDA ruling could turn the peptide portfolio into a long‑term catalyst. Amid this uncertainty, risk‑averse investors may target below $9.00 as a more cautious entry point.